Table 2

Multivariable model results using stepwise selection method* (with continuous BMI†) summarising OR (95% CI) for ACR50 response and estimates‡ (95% CI) for continuous outcomes at month 6

Tofacitinib dose
(twice daily)
ACR50 response∆DAS28-4(ESR)∆DAS28-4(CRP)∆CDAI∆HAQ-DI
5 mg10 mg5 mg10 mg5 mg10 mg5 mg10 mg5 mg10 mg
BMI category,† kg/m2
 25 to <30 versus <250.87
(0.67 to 1.12)
0.90
(0.69 to 1.16)
0.09
(−0.07 to 0.26)
0.11
(−0.05 to 0.27)
0.11
(−0.04 to 0.26)
0.11
(−0.04 to 0.25)
0.32
(−1.06 to 1.70)
0.36
(−0.90 to 1.61)
0.01
(−0.06 to 0.08)
0.02
(−0.05 to 0.09)
 ≥30 versus <250.94
(0.71 to 1.25)
0.80
(0.61 to 1.04)
0.07
(−0.11 to 0.25)
0.19
(0.03 to 0.36)
0.14
(−0.03 to 0.30)
0.21
(0.06 to 0.37)
−0.37
(−1.95 to 1.21)
0.44
(−0.91 to 1.79)
0.10
(0.03 to 0.18)
0.06
(−0.02 to 0.13)
BMI*0.99
(0.98 to 1.01)
0.98
(0.96 to 1.00)
0.01
(−0.01 to 0.02)
0.02
(0.01 to 0.03)
0.01
(0.00 to 0.02)
0.02
(0.01 to 0.03)
−0.03
(−0.13 to 0.07)
0.05
(−0.04 to 0.14)
0.01
(0.00 to 0.01)
0.00
(0.00 to 0.01)
Glucocorticoid use0.14
(0.01 to 0.26)
0.07
(0.01 to 0.13)
History of myocardial infarction−0.73
(−1.38 to −0.09)
−0.84
(−1.45 to −0.23)
−6.99
(−12.60 to −1.39)
MTX use0.78
(0.62 to 0.96)
0.26
(0.12 to 0.39)
0.21
(0.09 to 0.34)
1.52
(0.49 to 2.55)
0.14
(0.08 to 0.20)
0.14
(0.09 to 0.20)
Gender*
(male vs female)
1.32
(0.99 to 1.75)
1.32
(0.99 to 1.77)
−0.45
(−0.64 to −0.27)
−0.47
(−0.65 to −0.29)
−0.20
(−0.37 to −0.03)
−0.14
(−0.31 to 0.02)
−1.95
(−3.49 to −0.40)
−0.93
(−2.33 to 0.48)
−0.14
(−0.21 to −0.06)
−0.10
(−0.18 to −0.02)
Race
 White versus others2.86
(0.88 to 4.85)
2.81
(1.13 to 4.49)
0.13
(0.03 to 0.23)
0.14
(0.04 to 0.23)
 Black versus others0.72
(−2.91 to 4.34)
0.95
(−2.50 to 4.39)
0.07
(−0.12 to 0.25)
−0.03
(−0.22 to 0.15)
 Asian versus others2.00
(−0.18 to 4.18)
2.20
(0.29 to 4.10)
0.02
(−0.08 to 0.13)
−0.01
(−0.11 to 0.10)
Smoking status
 Smoker versus never smoked
0.09
(0.01 to 0.17)
 Ex-smoker versus never smoked−0.07
(−0.15 to 0.02)
TNFi failure0.70
(0.50 to 0.97)
0.12
(0.03 to 0.21)
0.14
(0.06 to 0.23)
Seropositivity
(yes vs no)
1.66
(1.20 to 2.29)
1.53
(1.15 to 2.03)
−0.24
(−0.44 to −0.03)
−0.25
(−0.43 to −0.07)
−0.35
(−0.53 to −0.17)
−0.29
(−0.45 to −0.13)
−3.46
(−5.11 to −1.82)
−1.86
(−3.20 to −0.53)
−0.14
(−0.23 to −0.06)
−0.13
(−0.20 to −0.05)
HAQ-DI0.16
(0.06 to 0.27)
1.07
(0.21 to 1.92)
−0.48§
(−0.52 to −0.43)
−0.48§
(−0.52 to −0.44)
Pain (VAS)1.00
(1.00 to 1.01)
0.00
(0.00 to 0.01)
0.03
(0.00 to 0.06)
SJC1.03
(1.01 to 1.04)
0.00
(−0.01 to 0.00)
TJC0.99
(0.98 to 1.00)
0.01
(0.01 to 0.02)
0.01
(0.00 to 0.02)
0.02
(0.01 to 0.02)
0.02
(0.01 to 0.02)
0.17
(0.10 to 0.23)
0.09
(0.04 to 0.15)
Age*0.99
(0.98 to 1.00)
0.99
(0.98 to 1.00)
0.00
(0.00 to 0.01)
0.00
(0.00 to 0.01)
0.00
(0.00 to 0.01)
0.00
(0.00 to 0.01)
0.02
(−0.03 to 0.07)
0.00
(−0.04 to 0.05)
0.01
(0.00 to 0.01)
0.01
(0.01 to 0.01)
Opioid use
(yes vs no)
0.52
(0.35 to 0.76)
0.29
(0.06 to 0.52)
0.36
(0.15 to 0.57)
0.22¶
(0.02 to 0.42)
3.91
(1.98 to 5.84)
2.02
(0.31 to 3.74)
Corresponding baseline value of response variable*N/AN/A−0.60
(−0.70 to −0.51)
−0.61
(−0.70 to −0.52)
−0.82
(−0.91 to −0.72)
−0.90
(−0.99 to −0.81)
−0.85
(−0.92 to −0.77)
−0.83
(−0.89 to −0.77)
−0.48
(−0.52 to −0.43)
−0.48
(−0.52 to −0.44)
  • Red text indicates statistical significance at p<0.05. For categorical variables with more than two levels, the pairwise comparisons are considered significant if both the overall and pairwise p values are <0.05. Covariates with blank cells were not selected in the multivariable model.

  • *Variables that were forced into the model included continuous BMI, age, gender and baseline value of the response variable.

  • †Categorical BMI was forced into a separate model using the same set of covariates. The ORs and estimates of the outcomes in this model are similar to those of the model with continuous BMI, except where indicated.

  • ‡For categorical BMI versus continuous outcomes, the estimate reflects the least squares mean difference between categories. For continuous BMI versus continuous outcomes, the estimate is the slope of the relationship.

  • §Included as baseline value of response variable.

  • ¶Included only in the model run with categorical BMI, but not the model with continuous BMI.

  • ∆, change from baseline; ACR, American College of Rheumatology; BMI, body mass index; CDAI, Clinical Disease Activity Index; DAS28-4(CRP), Disease Activity Score in 28 joints, C-reactive protein; DAS28-4(ESR), Disease Activity Score in 28 joints, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; N/A, not applicable; SJC, swollen joint count; TJC, tender joint count; TNFi, tumour necrosis factor inhibitors; VAS, Visual Analogue Scale.